About
Lawrence P. Guiheen became a director in July 2012 and chairs the Governance and Nominations Committee while also serving on the Audit and Compensation Committees. He has over 35 years of healthcare experience, including as Chief Commercial Officer of Kedrion Biopharma from 2013 to 2019 and more than 30 years at Baxter Healthcare, ending as President of BioPharmaceuticals US. He most recently served as Executive Vice President of Wellstat Management and Chief Executive Officer of Wellmond Therapeutics until retiring in March 2022.
Roles
Adma Biologics, Inc.
Director · Current role
2012–present
Wellstat Management / Wellmond Therapeutics
Executive Vice President / Chief Executive Officer · Wellmond Therapeutics was a start-up pharmaceutical company; retired in March 2022.
November 2019-March 2022
Kedrion Biopharma, Inc.
Chief Commercial Officer
July 2013-November 2019
Baxter Healthcare Corporation
President, BioPharmaceuticals US · Spent over 30 years at Baxter, most recently as General Manager Global Hemophilia Franchise and President of Global BioPharmaceuticals.
—
Director Compensation
FY 2025
Fees earned or paid in cash
$85,000
Stock awards (RSUs)
$174,986
Also at Adma Biologics, Inc.